Elizabeth Glaser Pediatric AIDS Foundation Announces Support for Pediatric HIV Treatment Agreement
Washington, D.C. (PRWEB) February 27, 2013
The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the collaboration between the Medicines Patent Pool (MPP) and ViiV HealthCare to provide a vitally important pediatric HIV medication to millions of children around the world.
ViiV Healthcare, a collaborative comprised of GlaxoSmithKline, Pfizer, and Shionogi, will provide the MPP with the license to abacavir, a World Health Organization (WHO)-recommended drug for pediatric HIV. Under the agreement, abacavir will be available in 118 countries, helping millions of children get the treatment they need to survive. In the future, MPP and ViiV Healthcare will work together to create low-cost versions of new medications for children living with HIV and AIDS.
“This is welcome news for the smallest patients living with HIV,” said Dr. Laura Guay, EGPAF vice president for research. “This partnership will help millions of HIV-infected children in the developing world access critical medicines to treat their infections and keep them alive and healthy.”
Children represent one out of every seven new HIV infections worldwide, but children lag far behind adults in treatment coverage. Only 28 percent of eligible children received antiretroviral therapy (ART) in 2011, compared with 58 percent of adults.
About the Elizabeth Glaser Pediatric AIDS Foundation:
EGPAF is a global leader in the fight against pediatric HIV/AIDS, and has reached more than 15 million women with services to prevent transmission of HIV to their babies. It currently works at more than 5,400 sites and in 15 countries to implement prevention, care, and treatment services; to further advance innovative research; and to execute global advocacy activities that bring dramatic change to the lives of millions of women, children, and families worldwide. For more information, visit http://www.pedaids.org.